What You Should Know:
-Tempus, an $8B precision medicine company, is providing genomic sequencing for 300 eligible pediatric cancer patients annually through their new collaboration with the Children’s Oncology Group (COG). Tempus’ support for COG – a leader in pediatric oncology research – will assist with matching patients to clinical trials like the Pediatric MATCH Screening Trial APEC1621SC (NCT03155620), which is studying the effectiveness of genetic testing-directed treatment in
Read More
Impact of Precision Medicine| News, Policy, Analysis, Insights - HIT Consultant
Techstars Relaunches Healthcare Accelerator in Los Angeles
What You Should Know:
- Techstars, a global investment business that provides access to capital, one-on-one mentorship, and customized programming for early-stage entrepreneurs announces today the relaunch of Techstars Healthcare sponsored by Cedars-Sinai, Point32Health, UCI Health, and UnitedHealthcare.
- The consortium-led accelerator program will be based in Los Angeles and select 12 high-growth startups to participate in its intensive 13-week program. Startups will receive capital,
Read More
What is the Potential for Digital Twins in Healthcare?
Digital twins are virtual representations of an object or system that spans its lifecycle, is updated from real-time data, and use simulation, machine learning and reasoning to help decision-making (IBM). In most cases, this helps data scientists understand how products are operating in production environments and anticipate how they may behave overtime. But what happens when a digital twin is that of a human being?
By using digital twins to model a person, you can use technologies like
Read More
How Medical Researchers Can Leverage Tech to Help Streamline Biospecimen Matchmaking and Procurement
Many medical advancements – from life-saving vaccines and treatments to new diagnostic tests like liquid biopsies – are built on research that involves human biospecimens. Biofluids, tissue and cells are indispensable resources for the medical researcher, yet the process of sourcing these biospecimens can be woefully frustrating and inefficient. These challenges can have a direct, negative impact on the pace of discovery, creating urgency for improved access to the biospecimens researchers need
Read More
Elevation Oncology Secures $50M Loan Facility with K2 HealthVentures
What You Should Know:
Elevation Oncology, a clinical-stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, today announced that it has secured a $50M senior secured loan facility from funds managed by K2 HealthVentures.
Elevation plans to use the funding from the facility will primarily support the exclusive license of EO-3021 (SYSA1801) outside of Greater China from CSPC Pharmaceutical Group and the
Read More
Syapse Raises $35M to Expand Learning Health Network
What You Should Know:
- Syapse raises $35M led by an affiliate of Innovatus Capital Partners, LLC (Innovatus)to tackle the challenge of understanding, preventing, and treating complex cancers.
- The investment will allow Syapse to expand its artificial intelligence and machine learning capabilities, making it more efficient to uncover meaningful insights from real-world oncology data.
Syapse, a San Francisco, CA-based real-world evidence company accelerating the
Read More
Mayo Clinic, Mercy Sign 10-Year Collaboration to Transform Patient Care
What You Should Know:
- Mayo Clinic and Mercy announced a 10-year collaboration agreement— a first-of-its-kind alliance between two large healthcare systems that will use the most current data science and years of deidentified patient outcomes to find diseases earlier and start patients on paths to better health more quickly.
- With the combination of privacy-protected, cloud-based technology architecture, and the growth of artificial intelligence and machine learning, this aggregated
Read More
Epic Integrates Caris Molecular Testing Portfolio with Epic’s ORA Network
What You Should Know:
- Caris Life Sciences (Caris), the leading molecular science and technology company today announced an enhanced partnership with Epic to integrate Caris' market-leading molecular testing portfolio with Epic's Orders and Results Anywhere (ORA) network.
- Caris builds upon its current Genomics Module integration within the nation's largest electronic health record provider by offering seamless ordering and receipt of Caris molecular profiling results directly in patient
Read More
Precision Medicine: Is Personalized Care Really Here?
What You Should Know:
- New Definitive Healthcare report, Is Personalized Care Really Here? analyzes the US claims data to review how precision medicine has been used in recent years for cancer, transplant matching, genetic testing during pregnancy and more.
- Trends within — and adjacent to — precision medicine suggests that consumer preferences for more effective, convenient and affordable care are driving rising rates of precision medicine procedures. Furthermore, the data reveal the
Read More
Proscia Raises $37M for AI-Enabled Pathology Platform
What You Should Know:
- Proscia, a Philadelphia-based provider of digital and computational pathology solutions raises $37M to advance the way we understand and treat diseases like cancer. The round includes participation from Highline Capital Management, Triangle Peak Partners, and Alpha Intelligence Capital as well as existing investors including Scale Venture Partners, Hitachi Ventures, ROBO Global, Emerald Development Managers, and Razor's Edge Ventures. This investment brings Proscia's
Read More
